AstraZeneca Pharma shares were in focus on Tuesday after its global parent reported better-than-expected results for the second quarter of 2025, driven by strong performance in its oncology portfolio.
For Q2, AstraZeneca reported revenue of $14.46 billion, ahead of the $14.12 billion estimate. Core earnings per share stood at $2.17, in line with projections, and the core operating margin remained steady at 32%.
One of the key highlights was Imfinzi, a major cancer drug, which clocked $1.46 billion in revenue, surpassing expectations of $1.34 billion.
The company declared an interim dividend of $1.03 per share and reiterated its full-year 2025 guidance, expecting high single-digit percentage growth in total revenue and low double-digit growth in core EPS.
AstraZeneca Pharma shares traded in a narrow range on July 29, moving between ₹8,865.50 and ₹9,000.00 during the session. The stock opened at ₹8,944.50, slightly above its previous close of ₹8,937.50. Despite the subdued movement, the stock remains significantly above its 52-week low of ₹6,220.00, though still below the 52-week high of ₹10,691.00.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
